Close Menu
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram
    Subscribe
    • Home
    • Top Stories
    • Business
    • Tech
    • Companies
    • Events
    • Announcements
    Home»BioTech»Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance
    BioTech

    Chiron AS Establishes State-of-the-Art Research Centre in Trondheim, Norway, Advancing Environmental Surveillance

    Marie JonesBy Marie JonesJanuary 18, 2024No Comments3 Mins Read
    Share
    Facebook Twitter LinkedIn Pinterest Email

    Chiron AS, a leading producer of chemical reference materials headquartered in Trondheim, Norway, is pleased to announce the establishment of a state-of-the-art research centre dedicated to the enhanced surveillance of environmental pollutants.

    This ground-breaking development, supported by an estimated 40 million NOK investment, reaffirms Chiron’s commitment to advancing the field of environmental analysis.

    The newly inaugurated research facility, which offers a 360-degree view of the Trondheim fjord, is equipped to address the most challenging pollutants of today, including microplastics and PFAS (commonly known as ‘forever chemicals’), and is poised to contribute significant research into environmental surveillance.

    This strategic relocation follows Chiron’s acquisition by Antylia Scientific in July 2023 and its successful incorporation into the ZeptoMetrix® Operating Division. The move to the new 1750 m2 premises aligns Chiron with Spex®, NSI Laboratories and High Purity Standards in strengthening the ZeptoMetrix Reference Material and Proficiency Testing portfolio.

    “We are excited to embark on this journey of heightened environmental surveillance,” Jon Eigill Johansen, Founder of Chiron AS, commented. “The establishment of our research centre highlights our commitment to scientific excellence. Through cutting-edge research and collaboration, we aim to support our mission to protect humans from undesired chemical exposure.”

    Evangeline Gonzalez, President of the ZeptoMetrix Operation Division, stated, “This investment reinforces our dedication to advancing environmental science. Chiron’s state-of-the-art research centre adds a crucial dimension to the ZeptoMetrix portfolio. This means we are even more ready to support our lab and industry partners with critical innovation as they work to address ongoing environmental challenges.”

    About ZeptoMetrix® 

    ZeptoMetrix, an Antylia Scientific Company, is the industry leader and manufacturer for innovative solutions solving challenges in the evolving Diagnostic Microbiology Infectious Disease, Oncology market and Analytical Reference Materials for the Applied Markets. We focus on our customers’ success by providing premium product quality, reliability, and expert technical knowledge, enabling our customers to develop and advance many applications across diagnostics, pharmaceutical, environmental, food and beverage industries. From in stock solutions to custom control and panel development through to launch, our scientific teams provide our customers with comprehensive, performance-oriented, and cost-effective products and services that positively impact the field of clinical diagnostics, analytical testing and contribute to a healthier world. ZeptoMetrix is an operating division of Antylia Scientific, a holding company of premier life science and diagnostic brands, including Cole-Parmer, Environmental Express and ZeptoMetrix.

    Contact Information
    Jennifer Button
    Deputy Director
    jenny.button@chiron.no
    +44(0)7963508499

    Related Files

    Chiron AS Establishes State-of-the-Art Research Centre.pdf

     

    View the original press release on newswire.com.

    ZeptoMetrix
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Telegram Email
    Previous ArticleMalaysian food startup Meals in Minutes raises $1.5m in Seed funding
    Next Article Global Advanced Metals Declared Conformant to Minerals Due Diligence Audit Standard for 14 Consecutive Years

    Related Posts

    Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease

    October 5, 2026

    Everest Medicines Announces the Acceptance and Priority Review of VELSIPITY(R) Manufacturing Localization Application by the Center for Drug Evaluation of China’s NMPA, Driving Continued Commercial Momentum

    October 2, 2026

    ESC 2026 Research Underscores the Burden of PSVT, Everest Medicines’ CARDAMYST(R) Offers an Out-of-Hospital, Self-Administered Treatment Option

    September 21, 2026
    Add A Comment
    Leave A Reply Cancel Reply

    Latest News

    • JCB Launches Premium Card Issuing Initiative for Affluent Customers in ASEAN Under Strategic Comprehensive Partnership with MUFG Bank
    • TMX Group Thanksgiving Holiday Market Closures
    • Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada
    • Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada
    • Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts
    • TIPAK Marks Path to Leadership in Packaging Solutions Following Listing on SET
    • Chervon Names Daniel L. Abbott Director of Sales – Western U.S.A.
    • Micot’s XTL6001 Featured in Two EASD Presentations: MasR/GCGR/GLP-1R Triple-Agonist Mechanism Opens a Differentiated Path Across Metabolic and Renal Disease
    • Savills Hong Kong Celebrates 40th Anniversary
    • Central New Energy (01735.HK) Receives MSCI Provisional ESG Rating of BB Under Semiconductor & Semiconductor Equipment Industry Model
    © 2026 BusinessNewsAsia.com
    • About Us
    • Contact Us
    • BusinessNews.ph
    • AsiaPEVC.com
    • DevFiNews.com
    • RenewableEnergy.ph

    Type above and press Enter to search. Press Esc to cancel.